Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

RecruitingOBSERVATIONAL

Enrollment

3,750

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

December 30, 2028

Study Completion Date

December 30, 2028

Conditions

RSV Infection

Interventions

DRUG

Nirsevimab

Immunoprophylaxis against RSV

Trial Locations (1)

RECRUITING

Yale Child Health Research Center, New Haven

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Yale University

OTHER